Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992;29(5):391-5.
doi: 10.1007/BF00686009.

Variability in the pharmacokinetics of epirubicin: a population analysis

Affiliations
Comparative Study

Variability in the pharmacokinetics of epirubicin: a population analysis

J R Wade et al. Cancer Chemother Pharmacol. 1992.

Abstract

Population pharmacokinetic analysis of the anticancer agent epirubicin was carried out using the program NONMEM. Data were available from 36 patients aged 20-73 years, of whom 23 were women. All subjects exhibited normal liver and renal function. Epirubicin was given as a short-term i.v. infusion over the dose range of 25-100 mg/m2, and an average of 11 plasma samples/subject were taken for a period of up to 72 h after each dose. A Two compartment model was fitted to the data, characterised by the parameters clearance, volume of the central compartment, alpha and beta. Clearance was tested as a linear function of various demographic and/or biochemical features. A significant proportion of the variability in clearance could be attributed to sex, and also to age in women. For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h. Such differences in clearance might be important in the selection of epirubicin dose regimens.

PubMed Disclaimer

References

    1. Cancer Chemother Pharmacol. 1987;20(1):71-4 - PubMed
    1. Cancer Treat Rep. 1982 Oct;66(10):1819-24 - PubMed
    1. Clin Pharmacokinet. 1989 Jun;16(6):327-36 - PubMed
    1. Cancer Chemother Pharmacol. 1982 Dec;10(1):11-5 - PubMed
    1. N Engl J Med. 1986 Feb 20;314(8):471-7 - PubMed

Publication types

MeSH terms